Inflarx (NASDAQ:IFRX) Posts Earnings Results, Beats Estimates By $0.20 EPS

Inflarx (NASDAQ:IFRX) announced its quarterly earnings data on Thursday. The company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.20, MarketWatch Earnings reports.

Shares of Inflarx stock opened at $8.43 on Friday. The stock has a market capitalization of $208.32 million, a price-to-earnings ratio of -3.76 and a beta of 0.53. Inflarx has a 1-year low of $2.17 and a 1-year high of $42.99. The firm’s 50-day moving average price is $6.13 and its two-hundred day moving average price is $4.16.

A number of research analysts have recently commented on IFRX shares. BMO Capital Markets upped their price objective on shares of Inflarx from $4.00 to $7.00 and gave the company a “market perform” rating in a research report on Thursday. ValuEngine raised shares of Inflarx from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. SVB Leerink increased their price target on shares of Inflarx from $4.00 to $7.00 and gave the stock a “hold” rating in a research report on Thursday, May 7th. Finally, Raymond James increased their price target on shares of Inflarx from $10.00 to $20.00 and gave the stock an “outperform” rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Inflarx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Featured Article: What strategies should day traders use to execute a trade?

Earnings History for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.